What drove DGX's EPS growth in Q3 2024?

Quest Diagnostics' (DGX) EPS growth in Q3 2024 was primarily driven by robust demand for its health tests, which led to increased revenues and operational efficiency.

1. **Health Tests Demand**: The demand for diagnostic tests has grown, especially among older adults, due to the prevalence of chronic diseases and the need for regular health screenings. This increase in demand has directly contributed to higher revenues for Quest Diagnostics.
2. **Strategic Acquisitions**: Quest Diagnostics has been focusing on strategic acquisitions to expand its service offerings and market reach. These acquisitions not only enhance the company's service portfolio but also contribute to increased revenues and potentially improved operational efficiencies, which can positively impact EPS.
3. **Operational Efficiency**: The company's emphasis on operational efficiency has likely led to better cost management and improved profitability margins, which can result in higher EPS. Quest Diagnostics has been working on streamlining its operations and leveraging technology to improve the quality and speed of its services, which can lead to increased productivity and better financial performance.

In summary, the EPS growth for Quest Diagnostics in Q3 2024 was driven by the robust demand for its health tests, strategic acquisitions, and operational efficiency. These factors collectively contributed to the company's financial performance and EPS growth during the quarter.